Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor

US7790727B2 · kind B2 · utility

Assignee

• Abbott GmbH & Co. KG · DE

Inventors

• Wilfried Braje · Ludwigshafen, DE
• Sean Colm Turner · Ludwigshafen, DE
• Andreas Haupt · Ludwigshafen, DE
• Udo Lange · Ludwigshafen, DE
• Karla Drescher · Ludwigshafen, DE
• Karsten Wicke · Ludwigshafen, DE
• Liliane Unger · Ludwigshafen, DE
• Mario Mezler · Ludwigshafen, DE
• Wolfgang Wernet · Ludwigshafen, DE
• Matthias Mayrer · Biblis, DE
• Ana Lucia Jongen-Relo · Hochdorf-Assenheim, DE
• Anton Bespalov · Ludwigshafen, DE
• Min Zhang · 安丰镇, CN

Key dates

• Filing date: Oct 31, 2008
• Grant date: Sep 7, 2010
• Expiry date: Oct 31, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D405/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to novel benzenesulfonanilide compounds of the formulae I and I′ and physiologically tolerated acid addition salts and the N-oxides thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT6 receptor.